 Home > Biochemistry News > Biotechnology News > CRISPR gene editing therapy aimed at functional cure of HIV infection is about to start phase 1 clinical trial

CRISPR gene editing therapy aimed at functional cure of HIV infection is about to start phase 1 clinical trial

 Last Update: 2021-09-18
 Source: Internet
 Author: User

Tags

ammonia based cleaner

chemical part 1

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 15, 2021, Excision BioTherapeutics announced that the US FDA has accepted the IND application for EBT-101

One of the reasons why HIV infection is difficult to cure is that the HIV virus can integrate the DNA into the genome of the host cell after reverse transcription of the RNA genome to produce DNA

EBT-101 is a therapeutic drug based on CRISPR gene editing in vivo.

Image source: Excision BioTherapeutics official website

Since CRISPR gene editing may produce off-target effects, and the repair process that connects DNA sequences after removal of proviral DNA may also introduce genetic mutations, this clinical trial will initially test the safety of the therapy and the efficiency of CRISPR to remove proviral DNA.

Reference materials:

[1] Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express aims to functionally cure HIV infection, CRISPR gene editing therapy is about to start phase 1 clinical trials

10-01

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

CRISPR gene editing therapy aimed at functional cure of HIV infection is about to start phase 1 clinical trial

Related Articles

Express aims to functionally cure HIV infection, CRISPR gene editing therapy is about to start phase 1 clinical trials